ArticleJAMA network open2023
Assessment of Median and Mean Survival Time in Cancer Clinical Trials.
Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.Molecular cancer therapeutics · 2026Article
- Evaluating Hemoglobin Thresholds for Blood Transfusions in Oncology Patients Admitted to the Intensive Care Unit.Journal of hematology · 2026Article
- Propensity Score Analysis of Second-Line Chemotherapy Outcome in Advanced Biliary Tract Cancer.Journal of clinical medicine · 2026Article
- Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227.Journal of thoracic disease · 2025Article
- The association of opioid prescribing continuity and the risk of opioid use disorder among older adults.Drug and alcohol dependence · 2025Article
- Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.Oral oncology · 2025Article
- Descriptive statistics for cardiothoracic surgeons: part 2 - the foundation of data interpretation.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.The oncologist · 2024Article
- Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.Leukemia · 2024Review
- Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.British journal of cancer · 2024Article
- Increase in the Life Expectancy of Patients with Cancer in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.PloS one · 2024Article
- Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.Seminars in radiation oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.